Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan, a multi-specialty healthcare company, has announced that the FDA has approved Latisse 0.03% as a novel treatment for hypotrichosis of the eyelashes.
Subscribe to our email newsletter
Latisse is said to be the first science-based treatment approved by the FDA to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.
Available only through a doctor, Latisse is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. Latisse users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks, the company said.
Latisse is expected to be available in the US by prescription only and is subject to all US guidelines applicable to dispensing a prescription product. Based on the FDA approval, Allergan expects to launch the product nationwide in the first quarter of 2009.
Scott Whitcup, executive vice president of R&D at Allergan, said: Latisse fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the FDA that increases the growth of eyelashes, making them longer, thicker and darker.